Skip to main content
micro-community-banner
 
  • Saved

Lilly

Sponsored
Do you consider your patients’ exon status when choosing treatment?

Tailor your 1st-line treatment for your patients with EGFR mut+ mNSCLC who have exon 21 (L858R) substitution.

Learn More

 

EGFR=epidermal growth factor receptor; mNSCLC=metastatic non-small cell lung cancer; mut+=mutation-positive.
PP-RB-US-3767 06/2022 © Lilly USA, LLC 2021. All rights reserved.

  • Saved

Commented on 's Post

Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung

Squamous cell carcinoma (SCC) of the lung has a markedly different molecular profile to adenocarcinoma of the lung and remains difficult to treat because of the lack of targeted therapies ..... see more

Source : https://www.clinical-lung-cancer.com/article/S1525-7304(22)00146-2/fulltext


Relevance: Squamous cell carcinoma (SCC) of the lung has a markedly different molecular profile to adenocarcinoma of the lung and remains difficult to treat because of the lack of targeted therapies for this type of non-small cell lung cancer (NSCLC). With immune checkpoint inhibitors moving from second-line treatment to first-line in NSCLC,...

Show More Comments

  • August 01, 2022
    Key Points • Source: Lung Cancer • Conclusion: “In order to ensure patients with SCC [squamous cell carcinoma] of the lung receive optimal treatment, genomic testing is essential to identify those patients who might Show More
  • Saved

made a Post

Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma

Pharmacogenomics is crucial for individualized drug therapy and plays an increasingly vital role in precision medicine decision-making. However, pharmacogenomics-based molecular subtypes and their potential clinical significance remain primarily unexplored in ..... see more

Source : https://www.sciencedirect.com/science/article/pii/S2001037022002781?via=ihub


Conclusion: We provided a novel molecular classification strategy and revealed three pharmacogenomics-based subtypes for LUAD patients, which uncovered potential subtype-related and patient-specific therapeutic strategies.

  • Saved

made a Post

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism - Clinical and Translational Oncology

Purpose Although lorlatinib, the third generation of echinoderm microtubule protein 4-anaplastic lymphoma kinase (EML4-ALK) tyrosine kinase inhibitor (TKI), overcame the previous generation ALK-TKIs' drug resistance problems, but the mechanism of ..... see more

Source : https://link.springer.com/article/10.1007/s12094-022-02884-x


Conclusion: This study demonstrated that the combination of p53 protein agonist and lorlatinib may provide a new therapeutic strategy for NSCLC patients with lorlatinib resistance and TP53 mutation. Furthermore, the results also provide guidance for selecting optimal chemo-regimens for NSCLC patients after ALK-TKIs failure.

  • Saved

made a Post

Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis - PubMed

1 Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 2 School of Public Health, LKS Faculty of Medicine, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35884423/


Conclusions: In patients from Asia with 19del, both EGFR-TKIs and treatments in which therapies were combined exhibited no OS benefits in comparison with standard chemotherapy treatments. Additional research is required to study TKIs' resistance mechanisms and possible combined approaches for individuals harboring this common mutation.

  • Saved

made a Post

Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition

We report a novel method to inhibit epidermal growth factor receptor (EGFR) signaling using custom morpholino antisense oligonucleotides (ASOs) to drive expression of dominant negative mRNA isoforms of EGFR by ..... see more

Source : https://www.liebertpub.com/doi/10.1089/nat.2021.0101


Relevance: We report a novel method to inhibit epidermal growth factor receptor (EGFR) signaling using custom morpholino antisense oligonucleotides (ASOs) to drive expression of dominant negative mRNA isoforms of EGFR by ASO-induced exon skipping within the transmembrane (16) or tyrosine kinase domains (18 and 21).

  • Saved

made a Post

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

There is an urgent and unmet need for more effective treatment options for patients with metastatic and recurrent non-small-cell lung cancer (NSCLC) who progressed on platinum-based therapy, immune checkpoint inhibitors ..... see more

Source : https://www.clinical-lung-cancer.com/article/S1525-7304(22)00147-4/fulltext


Conclusions: This is the first study to evaluate the safety and efficacy of ICI combined with docetaxel and ramucirumab. The findings could provide valuable information for developing new treatment strategies for NSCLC patients.

  • Saved

made a Post

De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report - PubMed

1 Department of Respiratory and Critical Care Medicine, The First People's Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, 311200, Zhejiang, China. 2 Department of Critical ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35866776/


Conclusions: This case reported a NSCLC patient with de novo mutation of EGFR-D761Y responding to third generation TKI Osimertinib.

  • Saved

made a Post

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship - Cancer Chemotherapy and Pharmacology

Purpose In RELAY, ramucirumab plus erlotinib (RAM + ERL) improved progression-free survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung cancer (NSCLC). Here, we present the exposure-response relationship of RAM ..... see more

Source : https://link.springer.com/article/10.1007/s00280-022-04447-x


Conclusions: No association was observed between RAM exposure and response, suggesting that the RELAY regimen of RAM 10 mg/kg Q2W with ERL is an optimized, efficacious, and safe first-line treatment for patients with untreated, metastatic, EGFR-mutated NSCLC.

  • Saved

made a Post

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non-small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded ..... see more

Source : https://ascopubs.org/doi/10.1200/JCO.22.00912


Conclusion: This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy. The safety was consistent with known toxicities of both drugs. These data warrant further evaluation.

  • Saved

made a Post

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

Int J Biol Sci 2022; 18(9):3845-3858. doi:10.7150/ijbs.70958 This issue Review Yueshui Zhao 1,3,4# , Sipeng Guo 1,3#, Jian Deng 1,3#, Jing Shen 1,3,4, Fukuan Du 1,3,4, Xu Wu 1,3,4, Yu ..... see more

Source : https://www.ijbs.com/v18p3845.htm


Relevance: The present review focuses on the angiogenic and non-angiogenic functions of VEGF in NSCLC, especially the interaction between VEGF and the cellular components of the TME. Additionally, we discuss recent preclinical and clinical studies to explore VEGF/VEGFR-targeted compounds and immunotherapy as novel approaches targeting the TME...

  • Saved

made a Post

Recombinant human erythropoietin accelerated the proliferation of non-small cell lung cancer cell lines and reduced the expression of VEGF, HIF-1α, and PD-L1 under a simulated hypoxic environment in vitro - PubMed

The effect of prolonged high concentrations of rhEPO under hypoxic conditions resulted in accelerated cells proliferation of non-small-cell lung cancer and was independent of EPOR expression levels on the cell ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35774428/


Conclusion: The effect of prolonged high concentrations of rhEPO under hypoxic conditions resulted in accelerated cells proliferation of non-small-cell lung cancer and was independent of EPOR expression levels on the cell lines surface. Hypoxia resulted in increased expression of VEGF, HIF-1α, and PD-L1 on the NSCLC cell lines. Under normoxic...

  • Saved

made a Post

Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Background . Lymph node metastasis is the most common and important way of metastasis in NSCLC and is also the most important factor affecting lung cancer stage and prognosis. It ..... see more

Source : https://www.hindawi.com/journals/ecam/2022/9693746/


Conclusion: The expression levels of Ki67, VEGF-A, and VEGF-C show a good potential for lymph node metastasis prediction.

  • Saved

made a Post

Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets - PubMed

From radiation therapy and surgery to chemotherapy and targeted therapy, the treatment of non-small cell lung cancer (NSCLC) has remarkably evolved over the past few decades. In recent years, immunotherapy ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35790251/


Relevance: Herein, we provide an overview of current popular cytokine and checkpoint inhibitor treatment regimens available for patients with NSCLC. Ongoing clinic trials and novel molecular targets that are discussed here could lead to promising new treatment options for NSCLC. The evidence summarized in this review might be helpful for...

  • Saved

made a Post

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis - PubMed

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive ( EGFR m+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35187947/


Conclusion: The analysis showed ramucirumab erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm advanced NSCLC.

  • Saved

made a Post

Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer

ABSTRACT Immune checkpoint inhibitors (ICI) are now utilized as a standard of care treatment for multiple cancers, including in both the metastatic setting as well as in earlier stages of ..... see more

Source : https://www.tandfonline.com/doi/abs/10.1080/14737140.2022.2094772?journalCode=iery20


Relevance: Immune checkpoint inhibitors (ICI) are now utilized as a standard of care treatment for multiple cancers, including in both the metastatic setting as well as in earlier stages of disease. The identification of unique immune-related adverse events (irAE) that occur during ICI treatment has led to intense research to identify...

  • Saved

made a Post

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics - BMC Cancer

Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages ..... see more

Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-09830-8


Conclusions: Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing...

  • Saved

Commented on 's Post

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? - PubMed

Reports on the efficacy of second-line treatment with cytotoxic agents after treatment with immune checkpoint inhibitors are limited. Here, we retrospectively evaluated patients in the real-world clinical practice treated with ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35740634/


Conclusion: “Our real-world data show that the addition of ramucirumab to docetaxel was superior to docetaxel monotherapy for improving time-to-treatment failure and overall survival, irrespective of previous treatment with immune checkpoint inhibitors.”

Show More Comments

  • from Oncology Nation July 04, 2022
    May be I am missing something but I thought it was proven long ago
  • Saved

Commented on 's Post



Conclusions: Results of this cohort study suggest that the option of virtual attendance at professional conferences may be associated with reduced carbon emissions. Numerous alternatives to in-person conference exist including (1) hosting hybrid conferences with both in-person and online attendance options, (2) alternating annual meetings...

Show More Comments

  • from Oncology Nation July 04, 2022
    it is also associated with reduced knowledge among doctors. decreased quality of care and increased chances for retirement among older folks